.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
US Army
Dow
Boehringer Ingelheim
Chinese Patent Office
Argus Health
Queensland Health
Julphar
Medtronic
Mallinckrodt

Generated: November 20, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,295,641

« Back to Dashboard

Which drugs does patent 9,295,641 protect, and when does it expire?


Patent 9,295,641 protects ALPHAGAN P and is included in two NDAs. There have been two Paragraph IV challenges on Alphagan P.

Protection for ALPHAGAN P has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-seven patent family members in nineteen countries.

Summary for Patent: 9,295,641

Title:Compositions containing alpha-2-adrenergic agonist components
Abstract: Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.
Inventor(s): Graham; Richard (Irvine, CA), Bakhit; Peter (Huntington Beach, CA), Olejnik; Orest (Coto De Caza, CA)
Assignee: ALLERGAN, INC. (Irvine, CA)
Application Number:14/484,017
Patent Claim Types:
see list of patent claims
Use; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Allergan
ALPHAGAN P
brimonidine tartrate
SOLUTION/DROPS;OPHTHALMIC021262-001Mar 16, 2001ATRXYesYes► Subscribe► SubscribeY
Allergan
ALPHAGAN P
brimonidine tartrate
SOLUTION/DROPS;OPHTHALMIC021770-001Aug 19, 2005RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 9,295,641

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,627,210 Compositions containing .alpha.-2-adrenergic agonist components► Subscribe
8,858,961Compositions containing alpha-2-adrenergic agonist components► Subscribe
9,687,443Compositions containing alpha-2-adrenergic agonist components► Subscribe
6,673,337 Compositions containing alpha-2-adrenergic agonist components► Subscribe
6,641,834 Compositions containing alpha-2-adrenergic agonist components► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,295,641

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
South Korea100757656► Subscribe
Australia2005280259► Subscribe
Brazil0109317► Subscribe
BrazilPI0514723► Subscribe
Canada2402405► Subscribe
Canada2474280► Subscribe
Canada2578784► Subscribe
China1460026► Subscribe
China100569291► Subscribe
China101897704► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Express Scripts
McKinsey
Cantor Fitzgerald
Mallinckrodt
Farmers Insurance
UBS
Citi
Moodys
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot